Quasney M W, Orman K, Thompson J, Ring J C, Salim M, Schoumacher R A, Watson D, Novick W, Deitcher S R, Joyner R
Department of Pediatrics, Crippled Children's Foundation Research Center, Memphis, TN 38103, USA.
Crit Care Med. 2000 Jun;28(6):2107-11. doi: 10.1097/00003246-200006000-00074.
To describe the use of aerosolized urokinase in a patient with plastic bronchitis after a Fontan procedure.
Case report.
Pediatric intensive care unit in a university-affiliated children's hospital.
Report of one patient with acute respiratory failure secondary to plastic bronchitis.
Aerosolized urokinase, multiple bronchoscopies, corticosteroids, mucolytics, bronchodilators, and atrial pacing.
Airway obstruction secondary to recurring casts improved with the treatments. Histologic analysis of the casts demonstrated less fibrin after treatments with aerosolized urokinase. No adverse events were noted.
The addition of aerosolized urokinase to this patient's treatment regimen helped to resolve life-threatening airway obstruction secondary to fibrin casts.
描述雾化尿激酶在接受Fontan手术的塑料支气管炎患者中的应用。
病例报告。
大学附属医院的儿科重症监护病房。
报告一例因塑料支气管炎继发急性呼吸衰竭的患者。
雾化尿激酶、多次支气管镜检查、皮质类固醇、黏液溶解剂、支气管扩张剂和心房起搏。
复发性铸型导致的气道阻塞经治疗后有所改善。对铸型进行组织学分析显示，雾化尿激酶治疗后纤维蛋白减少。未观察到不良事件。
在该患者的治疗方案中加入雾化尿激酶有助于解决纤维蛋白铸型继发的危及生命的气道阻塞。
